Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Neurology

An Iffy Future For Alkermes After Failed Trials

This article was originally published in Scrip

  • News

Executive Summary

You may also be interested in...



Keeping Track Of Bad News: Alkermes' Depression Candidate Gets Refuse To File; Teva/Celltrion Biosimilars Land CRLs

The dark side of US FDA review news this week. 

Keeping Track: A Little Bit Of (Nearly) Everything

The latest drug development news and highlights from our US FDA Performance Tracker.

If Alkermes Antidepressant Can Get Past FDA, The Market Might Be There

Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Neurology
Latest Headlines

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals

Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

See All
UsernamePublicRestriction

Register

SC064276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By